Positive new data has renewed the confidence of Chimeric Therapeutics in its pathway towards treating multiple types of cancer with its next generation armoured natural killer cell platform, “CHM0301”. The platform, which is being evaluated in its first clinical trial, has shown positive in vitro results in modelling human acute myeloid leukaemia and colorectal cancer by overcoming the resistance created by a tumour's microenvironment.
